rmdopen.bmj2d
Stability of symptom-based subtypes in Sjogren’s disease
5 Université Paris-Sud, Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM) UMR 1184, Université Paris-Saclay, Le ...
rmdopen.bmj7d
Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force
Objectives Evidence on the current status of gender equity in academic rheumatology in Europe and potential for its improvement is limited. The EULAR convened a task force to obtain empirical evidence ...
rmdopen.bmj5d
Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatment
Objective To assess whether gut microbiota composition is associated with patient characteristics and may have predictive value on the response to TNF inhibitor (TNFi) treatment in axial ...
rmdopen.bmj11d
Impact of assessing patient-reported outcomes with mobile apps on patient–provider interaction
Objective To explore the effect of apps measuring patient-reported outcomes (PROs) on patient–provider interaction in the rheumatic diseases in an observational setting. Methods Patients in the Swiss ...
rmdopen.bmj2d
Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to ...
rmdopen.bmj13d
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
Objective In the ORAL (Oral Rheumatoid Arthritis triaL) Surveillance study of patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor, incidence of pulmonary ...
rmdopen.bmj2d
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Objectives The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis. Methods ...
rmdopen.bmj10d
Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated
Objectives This study aims to assess current cardiovascular disease risk and prevalence of risk factors in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial ...
rmdopen.bmj5d
Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study
Introduction We aimed to compare the proportions of patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) remaining on methotrexate (regardless of other ...
rmdopen.bmj14d
Is rheumatoid arthritis always preceded by a symptomatic at-risk phase of arthralgia?
Objectives Secondary prevention of rheumatoid arthritis (RA) is generally considered potentially impactful because the entire ...
rmdopen.bmj19d
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
Objectives This post hoc analysis assessed speed, magnitude and maintenance of pain improvement in patients with early rheumatoid arthritis (RA) receiving baricitinib, baricitinib and methotrexate ...
rmdopen.bmj25d
Why does the gout attack stop? A roadmap for the immune pathogenesis of gout
Gout is one of the most severe and frequent rheumatic diseases. Clinical manifestations of gout arise from uric acid crystal deposition in the musculoskeletal tissue. At high concentrations of uric ...